Shelton Capital Management Has $803,000 Position in Illumina, Inc. (NASDAQ:ILMN)

Shelton Capital Management reduced its holdings in Illumina, Inc. (NASDAQ:ILMN) by 76.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 6,012 shares of the life sciences company’s stock after selling 20,049 shares during the quarter. Shelton Capital Management’s holdings in Illumina were worth $803,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ILMN. Integrated Wealth Concepts LLC boosted its holdings in shares of Illumina by 4.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,990 shares of the life sciences company’s stock worth $390,000 after buying an additional 135 shares during the period. Quantinno Capital Management LP boosted its holdings in shares of Illumina by 29.5% during the 3rd quarter. Quantinno Capital Management LP now owns 12,644 shares of the life sciences company’s stock worth $1,649,000 after buying an additional 2,879 shares during the period. Wellington Management Group LLP boosted its holdings in Illumina by 2.5% in the 3rd quarter. Wellington Management Group LLP now owns 30,946 shares of the life sciences company’s stock valued at $4,036,000 after purchasing an additional 755 shares during the period. Kovitz Investment Group Partners LLC bought a new stake in Illumina in the 3rd quarter valued at about $414,000. Finally, XTX Topco Ltd bought a new stake in Illumina in the 3rd quarter valued at about $226,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ILMN has been the subject of a number of recent research reports. Morgan Stanley cut their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Piper Sandler boosted their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Guggenheim cut their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Robert W. Baird cut their price objective on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Finally, TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and dropped their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $139.85.

Illumina Trading Up 8.5 %

NASDAQ:ILMN opened at $76.30 on Thursday. The company has a fifty day moving average of $90.77 and a 200 day moving average of $123.08. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $12.09 billion, a P/E ratio of -9.93, a P/E/G ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.